[New generation of insulins: glargine U300. Summary of clinical evidence].

Type 2 diabetes is a chronic, progressive disease with increasing prevalence and still late diagnostic. This leads to an increase in the incidence of chronic complications, with signifi cantly increasing health costs. There is also a delay in the onset of insulin therapy in patients with type 2 diabetes for causes related to both patients and physicians.

Treat-to-target HbA and lipid profile to prolong β-cell mass/function and optimize treatment goal attainment.

Background: To evaluate the relation between different serum lipid fractions and other known barriers to attain the HbA  ≤ 7.0% (53 mmol/mol) target.

Methods: Data on 2719 patients with type 2 diabetes were collected from the five waves of the International Diabetes Mellitus Practice Study implemented in Argentina (2006 to 2012) including demographic/socioeconomic profile, clinical, metabolic (HbA and serum lipids) data, and treatment type and also, percentage of treatment goal attainment.